抗真菌薬市場規模、シェア、成長分析、薬剤クラス別、適応症別、剤形別、流通チャネル別、地域別 - 産業予測、2024年～2031年

抗真菌薬の世界市場規模は2022年に144億米ドルと評価され、2023年の149億6,000万米ドルから2031年には203億2,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは3.90％で成長する見通しです。

世界の抗真菌薬市場は、アスペルギルス症やカンジダ症などの真菌感染症の有病率の上昇により大きな成長を遂げています。真菌感染症は、皮膚、目、口、膣の感染症のような全身および表在性の症状を含み、健康上の大きな懸念となっています。特に殺菌作用を持つ抗真菌薬は、水虫、白癬、真菌性髄膜炎など、さまざまな症状の治療に広く使用されています。市場の拡大は、院内感染やAIDSのような免疫系を低下させる疾患の発生率の増加によってさらに促進されています。真菌感染症は公衆衛生、特に免疫力が低下した人々にとって深刻な脅威となるため、抗真菌治療に対する需要は増加の一途をたどっており、市場成長の原動力となっています。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 技術分析
• バリューチェーン分析
• 市場のエコシステム
• ケーススタディ分析
• 規制情勢
• 主な投資の分析
• 主な成功要因
• 競合の程度
• PESTEL分析
• FDA承認抗真菌薬リスト
• 市場の魅力指数（2023年）

抗真菌薬市場：薬剤クラス別

• 市場概要
• アゾール
  • フルコナゾール
  • ボリカナゾール
  • ポサコナゾール
  • クロトリマゾール
  • その他
• エキノキャンディン
  • カスポファンギン
  • ミカファンギン
  • その他
• ポリエン
  • アムホテリシンB
  • その他
• アリルアミン
  • テルビナフィン
  • ナフチフィン
  • その他
• その他

抗真菌薬市場：適応症別

• 市場概要
• 皮膚糸状菌症
• アスペルギルス症
• カンジダ症
• その他

抗真菌薬市場：剤形別

• 市場概要
• 経口薬
• 軟膏
• 粉末
• その他

抗真菌薬市場：流通チャネル別

• 市場概要
• 病院薬局
• 小売店薬局
• その他

抗真菌薬市場：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Pfizer Inc.（US）
• Gilead Sciences, Inc.（US）
• Astellas Pharma Inc.（Japan）
• F. Hoffmann-La Roche AG（Switzerland）
• Sanofi S.A.（France）
• Bayer AG（Germany）
• Cipla Limited（India）
• Hetero Labs Limited（India）
• Hikma Pharmaceuticals PLC（UK）
• Galderma S.A.（Switzerland）
• Aurobindo Pharma（India）
• Cipla USA Inc.（US）
• Sandoz（a Novartis division）（Switzerland）
• Fresenius Kabi AG（Germany）
• Reddy's Laboratories Ltd.（India）
• Zydus Cadila Healthcare Ltd.（India）
• Eton Pharmaceuticals, Inc.（US）
• Pyxis Oncology（US）
• Incyte Corporation（US）

Global Antifungal Drugs Market size was valued at USD 14.4 billion in 2022 and is poised to grow from USD 14.96 billion in 2023 to USD 20.32 billion by 2031, growing at a CAGR of 3.90% during the forecast period (2024-2031).

The global antifungal drugs market is experiencing significant growth due to the rising prevalence of fungal infections such as aspergillosis and candidiasis. Fungal infections, which include both systemic and superficial conditions like skin, eye, mouth, and vaginal infections, are a major health concern. Antifungal drugs, particularly those with fungicidal properties, are widely used to treat a range of conditions, including athlete's foot, ringworm, and fungal meningitis. The market's expansion is further driven by the increasing incidence of hospital-acquired infections and diseases that compromise immune systems, such as AIDS. As fungal infections pose a serious threat to public health, particularly for individuals with weakened immune responses, the demand for antifungal treatments continues to rise, fueling market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antifungal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antifungal Drugs Market Segmental Analysis

Global Antifungal Drugs Market is segmented by Drug Class, Indication, Dosage Form, Distribution Channel, and region. Based on Drug Class, the market is segmented into Azoles, Echinocandins, Polyenes, Allylamines, and Others. Based on Indication, the market is segmented into Dermatophytosis, Aspergillosis, Candidiasis, and Others. Based on Dosage Form, the market is segmented into Oral Drugs, Ointments, Powders, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retails Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Antifungal Drugs Market

The growing prevalence of fungal and nosocomial infections is a key driver fueling the growth of the global antifungal drugs market. These infections, which can result from exposure to contaminated surfaces in healthcare settings or humid environments, are effectively treated with antifungal agents targeting both systemic and superficial conditions. Increased awareness of fungal diseases among the general public and healthcare professionals is further driving the demand for antifungal treatments. This heightened awareness, coupled with the rising incidence of fungal infections, is significantly contributing to the expanding market for antifungal drugs as patients and providers seek more effective treatment options.

Restraints in the Global Antifungal Drugs Market

A significant restraint in the global antifungal drugs market is the widespread lack of awareness regarding fungal infections, both among healthcare providers and the general public. This often results in undiagnosed cases, leading to delays in treatment or insufficient care. The limited understanding of these infections contributes to underdiagnosis and undertreatment, impacting patient outcomes. This restraint emphasizes the need for increased educational initiatives to raise awareness, improve diagnostic practices, and facilitate better communication between patients and healthcare providers. By addressing this gap, the healthcare community can enhance early detection and ensure more effective treatment, ultimately driving the growth of the antifungal drugs market.

Market Trends of the Global Antifungal Drugs Market

Continuous advancements in research and development within the antifungal drugs market present significant opportunities for the introduction of novel and more effective medications. Innovations in drug formulations, delivery systems, and therapeutic targets are improving treatment outcomes, addressing the growing demand for more efficient solutions. As pharmaceutical companies invest heavily in R&D, they can leverage these opportunities to develop cutting-edge antifungal drugs that meet evolving patient needs. This trend highlights the potential for enhanced therapeutic efficacy and expanded treatment options, fostering growth and competition within the market. The continued focus on innovation positions the industry for a transformative shift, with new therapies expected to play a key role in addressing various fungal infections.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Top Investment Analysis
• Key Success Factor
• Degree of Competition
• PESTEL Analysis
• FDA Approved Antifungal Drugs List
• Market Attractiveness Index, 2023

Antifungal Drugs Market by Drug Class

• Market Overview
• Azoles
  • Fluconazole
  • Voricanazole
  • Posaconazole
  • Clotrimazole
  • Others
• Echinocandins
  • Caspofungin
  • Micafungin
  • Others
• Polyenes
  • Amphotericin B
  • Others
• Allylamines
  • Terbinafine
  • Naftifine
  • Others
• Others

Antifungal Drugs Market by Indication

• Market Overview
• Dermatophytosis
• Aspergillosis
• Candidiasis
• Others

Antifungal Drugs Market by Dosage Form

• Market Overview
• Oral Drugs
• Ointments
• Powders
• Others

Antifungal Drugs Market by Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retails Pharmacies
• Others

Antifungal Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hetero Labs Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla USA Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (a Novartis division) (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila Healthcare Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eton Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pyxis Oncology (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments